Literature DB >> 7812621

Pharmacological characteristics of liriodenine, isolated from Fissistigma glaucescens, a novel muscarinic receptor antagonist in guinea-pigs.

C H Lin1, G J Chang, M J Su, Y C Wu, C M Teng, F N Ko.   

Abstract

1. The pharmacological activities of liriodenine, isolated from Fissistigma glaucescens, were determined in isolated trachea, ileum and cardiac tissues of guinea-pigs. 2. Liriodenine was found to be a muscarinic receptor antagonist in guinea-pig trachea as revealed by its competitive antagonism of carbachol (pA2 = 6.22 +/- 0.08)-induced smooth muscle contraction. It was slightly more potent than methoctramine (pA2 = 5.92 +/- 0.05), but was less potent than atropine (pA2 = 8.93 +/- 0.07), pirenzepine (pA2 = 7.02 +/- 0.09) and 4-diphenylacetoxy-N-methylpiperidine (4-DAMP, pA2 = 8.72 +/- 0.07). 3. Liriodenine was also a muscarinic antagonist in guinea-pig ileum (pA2 = 6.36 +/- 0.10) with a pA2 value that closely resembled that obtained in the trachea. 4. Liriodenine was 10 fold less potent in atrial preparations (left atria, pA2 = 5.24 +/- 0.04; right atria, pA2 = 5.35 +/- 0.09 and 5.28 +/- 0.07 for inotropic and chronotropic effects, respectively) than in smooth muscle preparations. 5. High concentration of liriodenine (300 microM) partially depressed the contractions induced by U-46619, histamine, prostaglandin F2 alpha, neurokinin A, leukotriene C4 and high K+ in the guinea-pig trachea. The inhibitions were characterized by a rightward shift in the concentration-response curves with suppression of their maximal contraction. 6. High concentration of liriodenine (300 microM) did not affect U-46619- or neurokinin A-induced tracheal contraction in the presence of nifedipine (1 microM) or in Ca(2+)-free (containing 0.2 mM EGTA) medium. 7. Neither cyclic AMP nor cyclic GMP content of guinea-pig trachealis was changed by liriodenine (30-300 microM). 8. It is concluded that liriodenine is a selective muscarinic receptor antagonist in isolated trachea, ileum and cardiac tissues of guinea-pigs. It is more potent in smooth muscle than in cardiac preparations. It also acts as a blocker of voltage-dependent Ca2+ channels at a high concentration (300 microM).

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7812621      PMCID: PMC1510049          DOI: 10.1111/j.1476-5381.1994.tb16205.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  32 in total

1.  Isolation, sequence, and functional expression of the mouse M1 muscarinic acetylcholine receptor gene.

Authors:  R A Shapiro; N M Scherer; B A Habecker; E M Subers; N M Nathanson
Journal:  J Biol Chem       Date:  1988-12-05       Impact factor: 5.157

2.  Differential regulation of PI hydrolysis and adenylyl cyclase by muscarinic receptor subtypes.

Authors:  E G Peralta; A Ashkenazi; J W Winslow; J Ramachandran; D J Capon
Journal:  Nature       Date:  1988-08-04       Impact factor: 49.962

3.  An M2 muscarinic receptor subtype coupled to both adenylyl cyclase and phosphoinositide turnover.

Authors:  A Ashkenazi; J W Winslow; E G Peralta; G L Peterson; M I Schimerlik; D J Capon; J Ramachandran
Journal:  Science       Date:  1987-10-30       Impact factor: 47.728

4.  Effects of phosphodiesterase inhibitors on normal and chemically-skinned isolated airway smooth muscle.

Authors:  S E Bryson; I W Rodger
Journal:  Br J Pharmacol       Date:  1987-11       Impact factor: 8.739

5.  Differential blockade of muscarinic receptor subtypes by polymethylene tetraamines. Novel class of selective antagonists of cardiac M-2 muscarinic receptors.

Authors:  C Melchiorre; A Cassinelli; W Quaglia
Journal:  J Med Chem       Date:  1987-01       Impact factor: 7.446

6.  Selectivity of muscarinic antagonists in radioligand and in vivo experiments for the putative M1, M2 and M3 receptors.

Authors:  H N Doods; M J Mathy; D Davidesko; K J van Charldorp; A de Jonge; P A van Zwieten
Journal:  J Pharmacol Exp Ther       Date:  1987-07       Impact factor: 4.030

Review 7.  Cholinergic control of airway smooth muscle.

Authors:  P J Barnes
Journal:  Am Rev Respir Dis       Date:  1987-10

8.  A muscarinic receptor with high affinity for pirenzepine mediates vagally induced bronchoconstriction.

Authors:  J W Bloom; H I Yamamura; C Baumgartener; M Halonen
Journal:  Eur J Pharmacol       Date:  1987-01-06       Impact factor: 4.432

9.  Cyclic nucleotides depress action potentials in cultured aortic smooth muscle cells.

Authors:  J M Ousterhout; N Sperelakis
Journal:  Eur J Pharmacol       Date:  1987-11-24       Impact factor: 4.432

10.  Methoctramine, a polymethylene tetraamine, differentiates three subtypes of muscarinic receptor in direct binding studies.

Authors:  A D Michel; R L Whiting
Journal:  Eur J Pharmacol       Date:  1988-01-05       Impact factor: 4.432

View more
  5 in total

1.  Mechanical effects of liriodenine on the left ventricular-arterial coupling in Wistar rats: pressure-stroke volume analysis.

Authors:  K C Chang; M J Su; Y I Peng; C C Shao; Y C Wu; Y Z Tseng
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

2.  Synthesis, characterization, and in vitro antitumor properties of gold(III) compounds with the traditional Chinese medicine (TCM) active ingredient liriodenine.

Authors:  Zhen-Feng Chen; Yan-Cheng Liu; Yan Peng; Xue Hong; Hong-Hong Wang; Min-Min Zhang; Hong Liang
Journal:  J Biol Inorg Chem       Date:  2011-09-30       Impact factor: 3.358

3.  Electrophysiological mechanisms for antiarrhythmic efficacy and positive inotropy of liriodenine, a natural aporphine alkaloid from Fissistigma glaucescens.

Authors:  G J Chang; M H Wu; Y C Wu; M J Su
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

4.  Antimuscarinic action of liriodenine, isolated from Fissistigma glaucescens, in canine tracheal smooth muscle.

Authors:  C H Lin; C M Yang; F N Ko; Y C Wu; C M Teng
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

5.  A novel muscarinic antagonist R2HBJJ inhibits non-small cell lung cancer cell growth and arrests the cell cycle in G0/G1.

Authors:  Nan Hua; Xiaoli Wei; Xiaoyan Liu; Xiaoyun Ma; Xinhua He; Rengong Zhuo; Zhe Zhao; Liyun Wang; Haitao Yan; Bohua Zhong; Jianquan Zheng
Journal:  PLoS One       Date:  2012-12-28       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.